Molecular Pathway Linked to Colorectal Cancer Progression
Researchers identified how specific proteins enable tumor growth and hinder chemotherapy effectiveness.
Updated on Sept. 24, 2026 in Cancer
Scientists have uncovered a molecular pathway involving the protein VASH2 that drives colorectal cancer progression and resistance to chemotherapy. This research highlights how certain proteins interact to support malignant cell survival.
Why it matters
Understanding the specific mechanisms that allow cancer cells to resist treatment and grow aggressively is essential for developing future therapeutic targets. Identifying these pathways provides a foundation for potential strategies to sensitize tumors to chemotherapy.
This molecular study, conducted in colorectal cancer (CRC) cell lines and tissues, found that VASH2 expression levels directly correlate with reduced chemosensitivity and increased tumor growth. The findings establish a causal link between VASH2 and malignant progression in laboratory models.
The details
The research shows that the protein VASH2 promotes the detyrosination of alpha-tubulin, a structural component of cells. This process prevents the degradation of YAP, a protein that drives cancer progression, by keeping YAP phosphorylation low. Additionally, the study found that the enzyme HDAC10 stabilizes VASH2 levels by preventing the protein from undergoing proteasomal degradation, effectively maintaining the oncogenic signal within the cancer cell.
Timeline
September 24, 2026: Research findings were published.
Health Landscape
This discovery adds to the growing map of molecular targets driving oncology research, specifically regarding how tumor architecture impacts drug resistance. The study advances the broader scientific effort seen in the NCI-MATCH clinical trial program to identify actionable molecular markers.
These findings are currently limited to laboratory research and do not change existing colorectal cancer treatment protocols today. Patients managing a cancer diagnosis should discuss their specific tumor's molecular testing options and established treatment plans with their oncologist.
The takeaway
This study highlights that proteins like VASH2 and HDAC10 act as critical gatekeepers for cancer cell survival and chemoresistance. Tracking the development of therapies that target these pathways is a useful area for those interested in the future of personalized oncology.
Further reading
For a broader look at current advancements in tumor biology and treatment, explore our Cancer section.
Source note: This article includes information reported by Nature.
